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Abstract
Background: Cancer cells simultaneously exhibit glycolysis with lactate secretion and mitochondrial respiration even 
in the presence of oxygen, a phenomenon known as the Warburg effect. The maintenance of this mixed metabolic 
phenotype is seemingly counterintuitive given that aerobic glycolysis is far less efficient in terms of ATP yield per moles 
of glucose than mitochondrial respiration.
Results: Here, we resolve this apparent contradiction by expanding the notion of metabolic efficiency. We study a 
reduced flux balance model of ATP production that is constrained by the glucose uptake capacity and by the solvent 
capacity of the cell's cytoplasm, the latter quantifying the maximum amount of macromolecules that can occupy the 
intracellular space. At low glucose uptake rates we find that mitochondrial respiration is indeed the most efficient 
pathway for ATP generation. Above a threshold glucose uptake rate, however, a gradual activation of aerobic glycolysis 
and slight decrease of mitochondrial respiration results in the highest rate of ATP production.
Conclusions: Our analyses indicate that the Warburg effect is a favorable catabolic state for all rapidly proliferating 
mammalian cells with high glucose uptake capacity. It arises because while aerobic glycolysis is less efficient than 
mitochondrial respiration in terms of ATP yield per glucose uptake, it is more efficient in terms of the required solvent 
capacity. These results may have direct relevance to chemotherapeutic strategies attempting to target cancer 
metabolism.
Background
Since its original discovery by Warburg [1] it has been
well established that most, if not all cancer cells are more
dependent on aerobic glycolysis for ATP production than
normal cells. The near uniform presence of this meta-
bolic phenotype in tumor cells is counterintuitive, as gly-
colysis produces only 2 moles of ATP per mole of glucose,
far less than the 36 generated by mitochondrial respira-
tion (Figure 1). Several hypotheses have been proposed
for the maintenance of this seemingly wasteful catabolic
state. At the cell population level, mitochondrial respira-
tion malfunction and enhancement of glycolysis are
thought to be a metabolic advantage under the intermit-
tent hypoxia conditions experienced by pre-malignant
and malignant tumor cells [2,3]. However, aerobic glycol-
ysis is not found exclusively in cancer cells, but is also
observed in rapidly dividing normal cells even under con-
ditions of normoxia [4]. It is also widely believed that the
glycolysis rate increases in order to match the increased
anabolic needs of the rapidly proliferating cells for pre-
cursor metabolites [5]. Yet, a focus on the cell's anabolic
needs alone neglects two important facts; First, in addi-
tion to precursor metabolites, growing cells need ATP to
meet the energy demands of biosynthetic pathways. Sec-
ond, in its original definition the Warburg effect refers to
the increase in the glycolysis rate ending in the excretion
of lactate, which does not contribute to the production of
precursor metabolites.
The actual molecular mechanisms that lead to the
enhanced aerobic glycolysis are increasingly well under-
stood. Under physiological condition, for example, PI3K/
Akt signaling pathways play a critical role in promoting
aerobic glycolysis in activated T cells in response to
growth factors or cytokines stimulation [6]. In the
pathophysiological condition of tumorigenesis, malfunc-
tion of mitochondrial respiration due to mitochondrial
DNA mutations/deletions is an important contributing
factor [7-10]. Also, p53, one of the most frequently
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Page 2 of 9mutated genes in cancers, is both a positive regulator of
mitochondrial respiration [11] and a negative regulator of
glycolysis [12]. These, together with the activation of
hypoxia-inducible factor (HIF), a transcription factor that
is activated by hypoxic stress but also by oncogenic, met-
abolic, and oxidative stress, often lead to the overexpres-
sion of the glucose transporters and various glycolysis
pathway enzymes or isozyme subtypes explaining the
increased glucose uptake and altered utilization [13,14].
The evidence accumulated so far thus indicates that the
presence of aerobic glycolysis is a common characteristics
of rapidly proliferating cells, and that it may offer a
growth advantage to rapidly proliferating normal cells,
e.g., during development and tissue regeneration, and to
cancer cells in tumor formation. Yet, a system-level inter-
pretation of the origin of this growth advantage has not
yet been formally provided. To start addressing this issue,
here we introduce a reduced flux balance model of ATP
generation that incorporates a glucose uptake capacity
constraint and the limited solvent capacity of the cell
cytoplasm. The model allows us to uncover the existence
of two different energetically favorable metabolic regimes
within proliferating cells, a finding that is congruent with
experimental results.
Results
Reduced flux balance model of cell metabolism
Figure 1 depicts a schematic model of glycolysis and
mitochondrial respiration, the main pathways for ATP
generation in cells. The glucose uptake flux (fG) is parti-
tioned into the flux of aerobic glycolysis (fL), and to oxida-
tive phosphorylation (fM). Aerobic glycolysis represents
Figure 1 Reduced model of cell metabolism. Schematic representation of ATP generation pathways via aerobic glycolysis (glycolysis + pyruvate 
reduction to lactate) and oxidative phosphorylation (glycolysis + mitochondrial respiration). The variable fG, denotes the glucose uptake rate, fL and fM, 
the components of the glucose uptake routed towards lactate excretion and respiration, respectively, and fATP the ATP production rate. Intermediate 
substrates of glucose catabolism are also used in a third process accounting for the production of precursor metabolites needed in anabolic processes 
(fP). The pathways considered in our model are shown in the gray-shaded area, while fP is treated as constant.
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Page 3 of 9glycolysis, converting glucose into pyruvate, and then
pyruvate reduction by lactate dehydrogenase (LDH) in
the cytosol, resulting in the end product lactate that is
then excreted to the extracellular millieau. ATP genera-
tion through oxidative phosphorylation is decomposed
into the generation of pyruvate through glycolysis, fol-
lowed by the oxidation of pyruvate in the TCA cycle and
the respiratory chain, the latter two processes taking
place in the cell's mitochondria. There is also a third com-
ponent for glucose utilization accounting for the produc-
tion of precursor metabolites needed in anabolic
processes (fP) (e.g., intermediate metabolites of the pen-
tose phosphate pathway and the TCA cycle [5]), which
have to have an overall proportionality with the available
energy currencies (phosphate donors, mainly ATP) to
enable cell growth. Thus, in the absence of a full scale
kinetic model, in our modeling we assume that the ATP
production rate (fATP) is proportional with the rate of ana-
bolic processes (fP), and use fATP as a surrogate for the
overall cell metabolic rate (Figure 1).
Aerobic glycolysis includes the glycolysis pathway pro-
ducing pyruvate and the pyruvate reduction producing
lactate. The overall reaction for aerobic glycolysis is
Aerobic glycolysis has a yield of 2 moles of ATP per
mole of glucose, resulting from the conversion of glucose
into lactate. On the other hand, oxidative phosphoryla-
tion includes the glycolysis pathway producing pyruvate,
the oxidation of pyruvate in the TCA cycle, and the respi-
ratory chain. The overall reaction of for oxidative phos-
phorylation is
Oxidative phosphorylation yields 38 moles of ATP per
mole of glucose, two of which are produced in glycolysis
and the other 36 during the oxidation of pyruvate in the
TCA cycle coupled to respiratory chain activity. Sum-
ming up these differential contributions we obtain the
rate of ATP production
where the second equality was obtained using fG = fL +
fM.
Our aim is to determine the optimal flux distribution
(fL, fM) that provides maximum ATP production rate
given the cell's metabolic constraints. Of these, the first
metabolic constraint is associated with the maximum
glucose uptake rate (or glucose uptake capacity)
where FG is the maximum glucose uptake rate. The sec-
ond constraint, quantified below, reflects on the high
concentration of macromolecules within the cell's cyto-
plasm [15,16], resulting in a limited solvent capacity for
the allocation of metabolic enzymes. Enzyme molecules
have a finite volume and the total sum of their volumes
cannot exceed the cell volume. In our case, this constraint
applies to the volume occupied by glycolytic enzymes,
LDH and mitochondria. Enzymes associated with other
pathways occupy a fraction of the intracellular volume as
well. Nevertheless, this fraction simply restricts the
amount of the cytoplasmic space available to glycolytic
enzymes, LDH and mitochondria. More precisely, if VG,
VL and VM are the cell volume occupied by glycolytic
enzymes, LDH and mitochondria, respectively, then
where VATP is the total cell volume reserved for the allo-
cation of components of the ATP producing pathways.
The occupied volumes VG, VL and VM are proportional to
the enzyme masses MG, ML and MM, with VG = vGMG, VL
= vLML and VM = vMMM, where vG, vL and vM are the spe-
cific volumes of glycolytic enzymes, LDH and mitochon-
dria, respectively. In turn, the glycolytic rate (fG), the
lactate excretion rate (2fL) and the mitochondrial ATP
production rate (36fM) are proportional to the mass of
glycolytic enzymes, lactate dehydrogenase and mitochon-
dria respectively, with fG = rGMG/V, 2fL = rLML/V and
36fM = rMMM/V, where rG is the glycolytsis rate per unit of
glycolytic enzyme mass, rL is the rate of lactate produc-
tion per mass of LDH, rM is the mitochondrial ATP pro-
duction rate per unit of mitochondrial mass, and V is the
cell volume. In these equations the product by the mass
and the division by the cell volume takes into account that
the rates r are commonly reported in the literature per
unit of dry weight, while the pathway rates f are reported
per unit of cell volume. Because of the interdependency
of volume, mass and reaction rate, the volume constraint
(5) can be translated to the metabolic constraint
where ϕ ATP = VATP/V is the total volume fraction of the
cell cytoplasm occupied by glycolytic enzymes, LDH and
mitochondria, and the crowding coefficients aG = vG/rG, aL
= 2 vL/rL and aM = 36 vM/rM quantify the occupied volume
fractions per unit of glycolytic, lactate excretion and
mitochondrial respiration rate, respectively. Using empir-
ical data reported in the literature we have estimated the
GLC 2 ADP 2 ATP 2 LAC 2 H O2+ → + + (1)
GLC 6 O 38 ADP 38 ATP 6 CO 6 H O2 2 2+ + → + +
(2)
f f f f fATP G M L M= + = +2 36 2 38 , (3)
f f f FL M G G+ = ≤ , (4)
V V V VG L M ATP+ + ≤ , (5)
( ) ( ) ,a a f a a fL G L M G M ATP+ + + ≤ f (6)
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0.0027 (min/mM), aL≈ 0.00023 (min/mM) and aM ≈ 0.10
(min/mM), indicating that the mitochondria contributes
about 5 and 50 times more to molecular crowding than
glycolytic enzymes and lactate dehydrogenase, respec-
tively. The unexpected consequences derived from this
fact will be uncovered below.
In our modeling we assume that VATP, rG, rL and rM are
constant parameters that can be obtained from experi-
mental estimates. Note though, that this is an approxima-
tion, as there may be regulatory mechanisms that under
certain environmental or developmental conditions are
capable of altering the amount of intracellular space allo-
cated to ATP producing pathways and the activity of glyc-
olytic enzymes, LDH and mitochondria.
Taken together the relevant metabolic optimization
problem is as follows: maximize the ATP production rate
(3) under the metabolic capacity constraints (4) and (6).
Optimal solution
In the following we discuss the model-predicted utiliza-
tion of aerobic glycolysis and oxidative phosphorylation
pathways in the context of the cell's glucose uptake rate. It
becomes obvious that the glycolysis rate matches the
maximum glucose uptake capacity (fG = FG) to maximize
the ATP production rate. However, there are some differ-
ences in the flux distribution along aerobic glycolysis and
oxidative phosphorylation depending on the glucose
uptake rate. Specifically,
for fG <f1, and for fG ≥ f1
where
The optimal solution is graphically illustrated in Figure
2a and 2b (lines). At low glucose uptake rates ATP is
entirely produced by the oxidative phosphorylation path-
way and there is no lactate production (and excretion).
This trend continues up to a threshold glucose uptake
rate, f1 (9), when mitochondria occupy the entire cell vol-
ume fraction (VATP) available for ATP production path-
ways (Figure 2a, blue dashed line, white background,
glucose-limited regime). Beyond this threshold value the
concentration of mitochondria, and therefore the rate of
ATP production through oxidative phosphorylation, can-
not be increased further. However, additional glucose
uptake may be diverted toward pathway(s) less efficient
in terms of ATP yield per mole of glucose. Indeed, the
optimal solution predicts a metabolic switch, in which
glucose uptake rates larger than f1 leads to a linearly
increasing lactate production (Figure 2a, red solid line,
gray background, space-limited regime), and therefore a
component of the ATP production is now derived from
aerobic glycolysis. Furthermore, the increase in lactate
production is accompanied by a slight, gradual reduction
of the oxidative phosphorylation flux (Figure 2a, blue
dashed line, gray background). Therefore, due to the
increased aerobic glycolysis rate ATP production can still
be increased beyond f1 (Figure 2b, green dotted line).
However, because aerobic glycolysis has a lower yield
than oxidative phosphorylation, the ATP production rate
increases with a lower slope beyond f1. Finally, it is worth
noting that because aM is 5 and 10 times higher than aG
and aL, respectively, these plots are not too sensitive to
the precise estimates of the crowding coefficients.
Indeed, assuming that aM is much greater than aG and aL,
we can approximate (8) by fM ≈ f1 and fL ≈ fG-f1. Therefore,
we predict that the plots of fM and fL versus fG are rather
universal, with a distinctive change of behavior at fG = f1.
Experimental evidence for model validity
The model described above results in two experimentally
testable predictions: the glucose uptake threshold f1 (9),
where the metabolic switch takes place, and the shape of
the lactate excretion, oxidative phosphorylation and ATP
production plots as a function of the glucose uptake rate.
To start addressing the validity of these predictions we
first utilized previously reported experimental data for
mouse LS cells [17] (Figure 2a, b), hybridoma cells [18]
(Figure 2c), and a mixture of cancer and normal cells [4]
(Figure 2d), indicating that cancer cells and normal cells
follow the same law.
In the first two cases [17,18], the growth rate of the cells
were manipulated by their growth in chemostat cultures
at different dilution rates, a protocol that is known to sub-
stantially vary the cells' glucose uptake rate. In both cases
the empirical lactate excretion plots (Figure 2a, c, red cir-
cles) follow the model predictions (Figure 2a, c, red solid
lines): at low glucose uptake rates there is no significant
lactate excretion, but once reaching a threshold the lac-
tate excretion rate increases linearly with the further
increase in glucose uptake rate. Moreover, the slope of
this linear increase coincides with that predicted by the
model. For the LS cells, we can also derive their oxidative
phosphorylation (Figure 2a, blue squares) and ATP pro-








f a a f f a a
f a a f f a a
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details), and in both cases we obtain a good agreement
between the experimental data (symbols) and the model
predictions (lines). In the third case, the mixture of can-
cer and normal cells is a compilation of experimental
reports using different methods and cell lines [4] (see also
Additional file 1 Table S4). Here again, glucose uptake
rates and lactate excretion levels show a good correlation
to each other (Figure 2d).
The glucose uptake threshold, i.e., the uptake rate
where the switch takes place, can be estimated from a lin-
ear fit to the lactate excretion plot in the regime where
lactate is excreted (Additional file 2 Figure S1). It ranges
between 0.8-1.0 mM/min for mouse LS cells, 0.37-0.54
Figure 2 Catabolic regimes within proliferating mammalian cells. a, b, c, d) Model-predicted (lines) and measured (symbols) fluxes as a function 
of the glucose uptake rate: a) and b) LS mouse cells, c) hybridoma cells and d) mixture of cancer and normal cells. The two different metabolic regimes 
are indicated by the white and gray backgrounds, respectively. All fluxes are reported in units of f1, the glucose uptake rate threshold, reported in panel 
e).
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mixture of cancer and normal cells (Figure 2e). Based on
independent empirical estimates of the cell volume frac-
tion occupied by mitochondria and the ATP production
rate per unit of mitochondrial mass, our model predicts
the threshold glucose uptake rate, f1, to be in the range
between 0.7 and 3.8 mM/min (Methods), which overlaps
with the ranges reported above for the different cell lines.
This agreement is surprisingly good given that they were
estimated using independent data.
To further test the model's predictive capability, we
have next examined human BJ fibroblast cells serially
transduced with the catalytic domain of human telom-
erase (hTERT), SV40 large T (LT) and small T (ST) anti-
gens, and an oncogenic allele of H-ras (H-RasV12) [19].
Previous studies using these cells have shown, as we par-
tially confirm here (Additional file 2 Figure S2), that the
growth rate, soft agar colony formation, and in vivo tum-
origenicity of CL1-[hTERT], CL2-[hTERT+LT], CL3-
[hTERT+LT+ST], and CL4-[hTERT+LT+ST+H-Ras] cells
largely correspond with their level of transduction [19],
and that their glucose uptake rates progressively increase
from normal toward more tumorigenic transformants
(CL1 to CL4)) [20]. Previous experiments also demon-
strated that normal CL1 cells display a severe reduction
in their ATP content upon inhibition of mitochondrial
oxidative phosphorylation, while the fully tumorigenic
CL4 cells remain largely unaffected (CL2 ad CL3 cells dis-
play an intermediate reduction in their ATP levels) [20].
In contrast, compared to the other three cell types CL4
cells display higher level of lactate production and a more
severe reduction in their ATP content when their LDH
activity is inhibited [20].
To confirm and extend the above findings, we experi-
mentally tested the extracellular lactate levels, mitochon-
drial mass and mitochondrial membrane potential (a
proxy for respiratory chain activity) of CL1-4 cells at 48 h,
72 h, 96 h, and 120 h after seeding the same amount of
cells, along with cell counts and total protein concentra-
tion measurements. We find that the tumorigenic CL4
cells have the highest extracellular lactate levels com-
pared to the other cell types at all time points tested that
correlates with a concomitant change in LDH enzyme
activity but not protein expression level (Additional file 2
Figure S3). CL4 cells also have the lowest mitochondrial
mass and membrane potential, though compared to CL1
cells their decrease is larger than predicted by our model
(Additional file 2 Figure S4) (a detailed description of the
results is given in the Additional file 2). Taken together,
the observed alterations in lactate production and mito-
chondrial parameters, together with the previously
observed oxidative phosphorylation and LDH activity
inhibition profiles in the same cells [20], are congruent
with the model predictions: an increase of lactate excre-
tion and decline of mitochondrial respiration with an
increasing replicative/tumorigenic capacity (quantified
by the ATP production rate in the model).
Discussion and conclusions
Rapidly proliferating mammalian cells, including cancer
cells, almost always exhibit aerobic glycolysis even under
normoxic conditions, characterized by an increased lac-
tate excretion rate relative to the respiration rate. Since its
original observation by Warburg [1], from the standpoint
of metabolic efficiency this has been a surprising obser-
vation because aerobic glycolysis is far less efficient than
mitochondrial respiration in terms of moles of ATP gen-
erated per mole of glucose. Implicit to this result, how-
ever, is the assumption that glucose uptake is a limiting
factor of cell metabolism. Yet, the validity of this assump-
tion on metabolic efficiency in the context of additional
physicochemical constraints of the cell has not been for-
mally addressed.
By developing a reduced flux balance model of ATP
production (Figure 1) here we demonstrate the existence
of two different metabolic regimes in mammalian cells,
depending on whether the cell metabolic rate is limited
by the glucose uptake or by the solvent capacity of the
cell's cytoplasm. In conditions where glucose transport
limits the cell's metabolic activity we find that the optimal
solution is to produce ATP entirely via mitochondrial res-
piration, confirming that ATP generation yield is the
appropriate measure within this regime; However, at high
glucose uptake rates the optimal solution is characterized
by an abrupt increase of the flux towards lactate produc-
tion (and excretion) and a gradual decrease of mitochon-
drial respiration (Figure 2). This second regime is
determined by the existence of a limited cytoplasmic sol-
vent capacity for allocating the components of the ATP
generating pathways (see equation (6)). For glucose
uptake rates exceeding the threshold level, f1, the cell can-
not further increase the concentration of mitochondria to
increase the respiration rate in order to match the
increased glucose uptake rate. Yet, the glucose uptake
"surplus" may now be diverted towards a pathway that is
less efficient in terms of ATP yield per mole of glucose
but is characterized by a higher rate of lactate (and thus
ATP) production per its own (i.e., glycolytic and LDH
enzymes) mass than the rate of ATP production by respi-
ration per mitochondrial mass.
Comparisons to experimental data reported for LS
mouse cells [17], hybridoma cells [18] and a collection of
normal and cancer cells [4] provide an indirect support
for the validity of these predictions. The agreement
between the experimentally determined fluxes and the
model predictions is remarkably good (see Figure 2). In
all cases the empirical plot of the lactate excretion as a
function of the glucose uptake rate (symbols) falls close to
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experimental values indicate a glucose uptake threshold
around 1 mM/min, which falls in the range f1~0.7-3.8
mM/min predicted by our model. Also, experimental
data reported here and previously [20] on lactate produc-
tion, mitochondrial parameters and enzyme inhibition
profiles of genetically modified human BJ fibroblast cells
[19] are congruent with the model's predictions. In simi-
lar recent experiments, oncogenic Ras/E1A transformed
low passage murine embryonic fibroblast (MEFs) (Ras-
LP) also displayed higher mitochondrial respiration activ-
ity and lower lactate secretion compared to more rapidly
dividing high passage MEFs (Ras-HP) [21], and tumor
progression in patients may correlate with reduced mito-
chondrial density and/or function [22-24].
The model described here has its limitations and does
not account for all the potential population-level advan-
tages of the Warburg effect. First, decreased mitochon-
drial respiration also contributes to the mitochondrial
depolarization that is frequently observed in tumor cells,
and that is thought to dampen the cell's propensity for
mitochondrially-induced apoptosis [25]. Secondly, the
effect of the secreted lactic acid on the surrounding nor-
mal tissue may increase the tumor cells' invasive potential
[3]. Thus, tumor cells may evolve to decrease mitochon-
drial respiration (and increase glycolysis) even further
than predicted by our model. Third, increased glycolytic
rates can increase the sensitivity of the pathways produc-
ing precursor metabolites to specific regulators, allowing
high rates of proliferation when required [26]. Moreover,
our simplified model focuses on the ATP demand and the
cell volume fraction occupied by mitochondria. However,
in addition to ATP rapidly proliferating cells need
increased amount of precursor metabolites to fuel their
biosynthetic pathways [5,27]. Thus, ultimately a cell-scale
metabolic model will need to be developed to take into
account all the cell's metabolic demands. The achieve-
ment of this goal is currently limited by the unavailability
of enzyme activity measurements at the human metabolic
network scale.
From a more general perspective, it is evident that aero-
bic glycolysis is not unique to cancer- and rapidly prolif-
erating normal mammalian cells but is present in
unicellular organisms, as well. For instance, under aerobic
growth conditions fast growing E. coli and S. cerevisiae
cells also exhibit aerobic glycolysis, resulting in the excre-
tion of the metabolic byproducts, acetate and ethanol,
respectively. More importantly, both for E. coli and for S.
cerevisiae a shift toward aerobic glycolysis follows a
switch from limited to rich nutrient conditions [28,29],
and for E. coli the maximum growth rates in different car-
bon sources and the mode of utilization of mixed carbon
sources are in agreement with those allowed by the lim-
ited solvent capacity of the cell's cytoplasm [29,30]. Taken
together with our current finding for mammalian cells,
these results suggest that the appearance of aerobic glyco-
lysis provides an energetically favorable catabolic state for
all rapidly proliferating cells due to the inherent physico-
chemical constraint of molecular crowding on cell metab-
olism.
These results may have relevance to cancer therapy as
well. It has been previously proposed that the Warburg
effect may represent a unique property of cancer cell
metabolism [13]. Pharmacological reduction of lactate
production and excretion may indeed reduce the invasive
potential of tumor cells or makes them more susceptible
to apoptosis [25]. However, the metabolic state of tumor
cells itself is not a unique target for cancer chemotherapy,




aG: The glycolysis rate per total mass of glycolytic enzyme
is about rG = 0.29 mmol glucose uptake/min/g at 30°C
[31], obtained as 23 μmol/min/mL lactate production
rate (Table four [31]), divided by 40 mg/mL of total glyco-
lytic protein concentration (Table two [31]), and divided
by 2 to convert from lactate production to glucose
uptake. The specific volume of glycolytic enzymes is esti-
mated from the specific volume of globular proteins 0.79
mL/g [32], thus we use vG = 0.79 mL/g. Putting these two
values together we obtain aG = vG/rG = 0.0027 (min/mM).
aL: The rate of lactate production per mass of lactate
dehydrogenase is about rL = 7 mmol lactate/min/g at 30°C
[31], obtained as 23 μmol/min/mL lactate production
rate (Table four [31]), divided by 3.2 mg/mL of lactate
dehydrogenase concentration (Table two [31]). The spe-
cific volume of lactate dehydrogenase is estimated from
the specific volume of globular proteins 0.79 mL/g [32],
thus we use vL = 0.79 mL/g. Putting these two values
together we obtain aL = 2vL/rL = 0.00023 (min/mM). aM:
The mitochondrial rate of ATP generation per mitochon-
drial mass is in the range of 0.1-1.0 mmol ATP/min/g [33-
35]. We use the maximum value rM = 1.0 mmol ATP/min/
g. The mitochondrial specific volume has been reported
to be 3.15 mL/g in mammalian liver [36] and 2.6 mL/g in
muscle [37], respectively. We use the average between
these two values vM = 2.9 mL/g. Putting these two values
together we obtain aM = 36vM/rM = 0.10 (min/mM). ϕATP:
The cell volume fraction occupied by cellular compo-
nents involved in the generation of ATP was estimated
from the cell volume fraction occupied by mitochondria.
Literature reports for the latter range between 0.07 in
some cell lines to 0.38 in muscle cells (Additional file 2
Table S1). Thus we use ϕATP = 0.07-0.38. f1: Substituting
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0.0027 (min/mM) and ϕATP = 0.07-0.38 into (9) we obtain
f1 = 0.7-3.8 mM/min.
Parameter estimates: flux data
Murine LS cells: The experimental flux measurements for
the mouse LS cell line were obtained from reference [17]
(Additional file 1 Table S2), reporting the glucose uptake,
lactate production and oxidized glucose rates, in units of
μmole per 106 cells per day. The experimental value of f1
was estimated from a linear fit to the data points in the
region where there is a significant lactate production
(Additional file 2 Figure S1a), resulting in f1 = 0.69 μmole
per 106 cell per day. Taking into account that LS mouse
cells have a typical volume of 500-600 μm3 [38] we obtain
f1 = 1 mM/min. Hybridoma cells: The experimental flux
measurements for the hybridoma cell line were obtained
from reference [18] (Additional file 2 Table S3), reporting
the glucose uptake and lactate production rates, in units
of mmole per 109 cells per hour. The experimental value
of f1 was estimated from a linear fit to the data points in
the region where there is a significant lactate production
(Additional file 2 Figure S1b), resulting in f1 = 0.042
mmole per 106 cells per hour. Taking into account that
hybridoma cells have a typical volume of 1300-1900 μm3
[39] we obtain f1 = 0.37-0.54 mM/min. Mixture of cancer
and normal cells: The experimental flux measurements
for the mixture of cancer and normal cells were obtained
from reference [4] (Additional file 1 Table S4), reporting
the glucose uptake and lactate production rates, in units
of mmol/g/h. The experimental value of f1 was estimated
from a linear fit to the data points in the region where
there is a significant lactate production (Additional file 2
Figure S1c), resulting in f1 = 0.029 mmol/h/g. Assuming a
typical cell density of 0.34 g/mL we obtain f1 = 1.4 mM/
min.
Experimental Protocols
Genetically-manipulated derivatives of human BJ fibro-
blasts, transfected with the catalytic subunit of human
telomerase (hTERT) (CL1), hTERT+ SV40 large T (LT)
(CL2), hTERT+LT+ SV40 small T (ST)(CL3), and
hTERT+LT+ST+ V12 mutant human Ras (Ras) (CL4) [19]
were generous gifts from Dr. W. Hahn (Dana Farber Can-
cer Institute, Boston). The cells were maintained in
DMEM supplemented with 25 mM glucose, 4 mM glu-
tamine and 10% FBS at 37° in a CO2 incubator with 5%
CO2 and 95% air. The experimental protocols for Western
blots, Ras activity measurements cell growth and soft
agar assays, LDH activity measurements, and for measur-
ing mitochondrial mass and membrane potential are pro-
vided in the Additional file 2.
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